Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
We review which stablecoins fall under regulatory scrutiny, the regimes that apply, and practical implications for users and providers alike.
19,598 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
MiMedx (MDXG) 2025 earnings scrutiny goes beyond one quarter. This guide breaks down what to watch in the Q4 call, ho...
A small-cap space stock can swing wildly, but patient, disciplined investors can map out potential outcomes. This gui...
Netflix is pivoting toward ads and international growth. This article breaks down the netflix's revenue expected surg...
When kevin warsh's inflation testimony landed, traders priced an 86% chance of a Fed rate hold. This article breaks d...
Explore how Permian Resources could navigate 2025 earnings, debt reduction, and growth opportunities. Learn who benef...
A Chicago-area widow faces a higher tax bill after converting $25,000 to a Roth. The move cost her Senior Freeze prot...
Monster Beverage's 2025 earnings outlook centers on international growth, margin improvements, and strategic branding...
A Chinese open-weights AI model stirred markets and sent Nvidia shares lower. This piece explains why the dip could a...
The bitcoin price rally riding on record U.S. margin debt has traders on edge. Analysts warn a swift unwind could arr...
Tensions around Yemen’s Houthis could disrupt a key oil route and set off a chain reaction in markets. This guide exp...
Institutional moves are reshaping exposure to China as the market resets. This article explains what happened with mi...